Ignite Creation Date:
2024-05-05 @ 12:09 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00252746
Status:
COMPLETED
Last Update Posted:
2016-08-25
First Post:
2005-11-14
Brief Title:
ZD6474 Phase IIa Dose Finding Multicentre Study
Sponsor:
Genzyme a Sanofi Company
Organization:
Sanofi
Study Overview
Official Title:
A Randomised Double-blind Parallel-group Dose Finding Study to Assess the Efficacy and Safety of ZD6474 in Patients With Advanced Metastatic or Recurrent NSCLC Who Have Failed Previous Chemotherapy Regimens at Least One of Which Contained Platinum Title Abbreviated
Status:
COMPLETED
Status Verified Date:
2016-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To assess the objective response rates by RECIST to ZD6474 100 200 and 300 mgday respectively
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None